

Complementary and Alternative Therapies in IBD

Complementary and alternative therapies encompass a range of medicinal, psychological or physical therapies that are not considered conventional treatment.

What is the difference between complementary and alternative therapies?

Complementary therapies are therapies used together with conventional treatments prescribed by your inflammatory bowel disease (IBD) team. Alternative therapies, however, are those used instead of conventional treatments. While complementary therapies may play a role in your treatment, we generally do not recommend using non-conventional therapies as an alternative to conventional treatments. If you are using or are interested in using complementary therapies, we suggest discussing this with your IBD team.

Are there complementary therapies that are helpful for inflammatory bowel disease?

Many people are interested in complementary therapies, but more research is needed in this area. Some studies have shown that complementary therapies may help some bowel symptoms, pain, or contribute to improving your quality of life and well-being. Some therapies may have a positive effect on bowel inflammation as well. It is worthwhile discussing this with your IBD team if you are interested. See the below table for a few therapies that have been investigated.

Can complementary/alternative therapies cause harm?

Just as some of these therapies may cause a beneficial effect, they may also cause side effects or have interactions with your other medications. Unfortunately, their safety may not have been well-studied. It is best to inform your IBD team about the use of complementary or alternative therapies.

There are many products or websites claiming success or cures from complementary and alternative therapies in IBD – how should I approach them?

There is no evidence that IBD can be cured by complementary or alternative therapies. While many products or websites can be found claiming the effectiveness or even cures from various complementary or alternative therapies, these should be viewed with caution. The regulation of production and advertising of non-conventional therapies is very different to conventional therapies, so claims can be made without any scientific evidence to support them.

Table: Some commonly asked questions about complementary therapies in IBD

Acupuncture +/- Moxibustion	There are some studies indicating a possible benefit of acupuncture +/- moxibustion in IBD patients. However, there is no agreed technique and the quality of the studies is variable. They appear to be safe.
Aloe Vera	There is some evidence from a small study in ulcerative colitis patients to suggest that aloe vera gel, 100mL twice daily, may improve clinical activity and appears to be safe.
Cannabinoids (eg. CBD)	There is some evidence to support cannabinoids reducing symptoms, but no quality evidence in humans to suggest they reduce inflammation or prevent complications associated with IBD. There may also be some harms to the use of cannabinoids.
Curcumin/Turmeric	There is some evidence to support the use of curcumin, the main active ingredient of turmeric, in the induction and maintenance of remission in patients with ulcerative colitis on 5-ASA therapies only. Suggested doses are 1-3 g per day.
Exercise	There is some evidence suggesting a role for exercise in preventing IBD development or a flare up. Recommendations regarding the best type and intensity of exercise are unknown. However, regular exercise can have benefits on overall physical and mental health and quality of life.
Meditation, mindfulness and relaxation	Meditation, mindfulness and relaxation may have a positive effect on mental health, quality of life and IBD symptoms, with no known associated harm. Please refer to the Mental Health and IBD information sheet .
Probiotics	There is currently no good quality evidence to support the use of probiotics in Crohn's disease. In ulcerative colitis and pouchitis, some formulations have been found to be effective – you should discuss this with your treating team if you are interested.

Acknowledgements:

This resource was developed in 2021 by the **GESA IBD Patient Information Materials Working Group** that included the following health professionals:

Mayur Garg (Chair, Gastroenterologist)	Susan Connor (Gastroenterologist)	Heidi Harris (IBD Clinical Nurse Consultant)	Marion O'Connor (IBD Clinical Nurse Consultant)
Aysha Al-Ani (Gastroenterologist)	Sam Costello (Gastroenterologist)	Katherine Healy (Senior Gastrointestinal Dietitian)	Meera Rajendran (IBD Pharmacist)
George Alex (Gastroenterologist - Paediatric)	Basil D'Souza (Colorectal Surgeon)	Simon Knowles (Specialist Gastrointestinal Psychologist)	Clarissa Rentsch (IBD Pharmacist)
Vinna An (Colorectal Surgeon)	Alice Day (Senior Gastrointestinal Dietitian)	Taryn Lores (Health Psychologist)	Sally Stockbridge (CCA Consumer Representative)
Jakob Begun (Gastroenterologist)	Kevin Greene (Consumer Representative)	Raphael Lubet (Gastroenterologist)	Julie Weldon (CCA Consumer Representative)
Maryjane Betlehem (Stomal Therapy Nurse)	Geoff Haar (IBD Pharmacist)	Antonina Mikocka-Walus (Specialist Gastrointestinal Psychologist)	Charys Winter (IBD Clinical Nurse Consultant)
Robert Bryant (Gastroenterologist)	Emma Halmos (Senior Gastrointestinal Dietitian)		
Britt Christensen (Gastroenterologist)	Tim Hanrahan (Gastroenterology Trainee)		
Rosemary Clerehan (Educational Linguist)			

Requests and enquiries concerning reproduction and rights should be addressed to: Gastroenterological Society of Australia (GESA)
Level 1 517 Flinders Lane Melbourne VIC 3000 | Phone: 1300 766 176 | email: gesa@gesa.org.au | Website: <http://www.gesa.org.au>

This document has been prepared by the Gastroenterological Society of Australia and every care has been taken in its development. The Gastroenterological Society of Australia and other compilers of this document do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information. This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use, or use within your organisation. Apart from any use as permitted under the Copyright Act 1968, all other rights are reserved. © 2021 Gastroenterological Society of Australia ABN 44 001 171 115.